Navigation Links
U of Minnesota finalizes license agreement to form start-up company based on Doris Taylor research
Date:2/16/2010

A major step in commercializing the groundbreaking research of Dr. Doris Taylor was achieved recently when the University of Minnesota signed an exclusive, global license agreement with Miromatrix Medical Inc. Dr. Taylor's research garnered worldwide attention in 2008 when her team announced that it had created a beating animal heart in her laboratory.

The technology licensed to Miromatrix holds the promise of one day enabling the replacement of entire human organs with non-transplantable organs, harvested from either animals or donors, which are stripped of their cells and recellularized with cells from the recipient or compatible donor cells.

"This is a major step forward for our technology commercialization efforts," said Tim Mulcahy, the University's vice president for research. "We took a methodical approach to this start-up and licensing agreement due to the tremendous potential of Dr. Taylor's research which, we believe, holds the potential to launch an entirely new industry on the scale of the medical device industry."

The agreement, negotiated by the university's Office for Technology Commercialization, includes equity for the university as well as future royalty and sublicensing fees.

"Miromatrix intends to commercialize a series of products based upon Dr. Taylor's platform as efficiently as possible, utilizing our own internal development as well as external collaborations," said CEO Robert Cohen. "Dr. Taylor's close involvement with the company will be tremendously beneficial as we ramp up this development effort."

Cohen joined Miromatrix as CEO in mid-November 2009. He was vice president of business and technology development at St. Jude Medical, and a former CEO of Travanti Pharma Inc. and Advanced Circulatory Systems, Inc., after holding top positions with the Pfizer Hospital Products Group and Sulzer Medica. Once Cohen joined the company, he and the University worked quickly to iron out the business and legal terms in the license agreement.

According to Cohen, Miromatrix expects to complete its initial round of financing in the next few months.


'/>"/>

Contact: Patty Mattern
mattern@umn.edu
612-624-2801
University of Minnesota
Source:Eurekalert

Related biology news :

1. University of Minnesota research leads to new technology to protect human health
2. Environmental cues control reproductive timing and longevity, University of Minnesota study shows
3. U of Minnesota-led study finds that hunters are depleting lion and cougar populations
4. Minnesota Counties Secure New Criminal Charging System With BIO-key(R) Fingerprint Biometrics
5. U of Minnesota research reveals critical role of evolutionary processes in species coexistence
6. U of Minnesota study finds high school teachers influence student views of evolution & creationism
7. Concerns about food safety to be spotlighted at U of Minnesota symposium
8. U of Minnesota research finds most road salt is making it into the states lakes and rivers
9. Small male chimps use politics, rather than aggression, to lead the pack, U of Minnesota study says
10. Hobbit fossils represent a new species, concludes University of Minnesota anthropologist
11. U of Minnesota researcher finds link between aggression, status and sex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... 2017 On Thursday, March 23, ... 5,817.69, down 0.07%; the Dow Jones Industrial Average edged ... 500 closed at 2,345.96, marginally dropping 0.11%. US markets ... green, 4 sectors finished in red, and 1 sector ... initiated reports coverage on the following Biotechnology equities: BioDelivery ...
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... selected by the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® ... annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished in ...
(Date:3/23/2017)... -- In today,s pre-market research, Stock-Callers.com takes ... industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals Inc. ... Regulus Therapeutics Inc. (NASDAQ: RGLS ). On ... rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more about ... ...
Breaking Biology Technology: